Daryl E Morris
Overview
Explore the profile of Daryl E Morris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frank I, Li S, Grunenberg N, Overton E, Robinson S, Zheng H, et al.
Lancet HIV
. 2024 May;
11(5):e285-e299.
PMID: 38692824
Background: An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate...
2.
Cohen K, Fiore-Gartland A, Walsh S, Yusim K, Frahm N, Elizaga M, et al.
J Clin Invest
. 2023 Feb;
133(4).
PMID: 36787249
BACKGROUNDMosaic and consensus HIV-1 immunogens provide two distinct approaches to elicit greater breadth of coverage against globally circulating HIV-1 and have shown improved immunologic breadth in nonhuman primate models.METHODSThis double-blind...
3.
Bekker L, Moodie Z, Grunenberg N, Laher F, Tomaras G, Cohen K, et al.
Lancet HIV
. 2018 Jun;
5(7):e366-e378.
PMID: 29898870
Background: Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted...
4.
Sneller M, Justement J, Gittens K, Petrone M, Clarridge K, Proschan M, et al.
Sci Transl Med
. 2017 Dec;
9(419).
PMID: 29212716
Despite substantial clinical benefits, complete eradication of HIV has not been possible using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral reservoirs or boost host immunity to...
5.
Zolla-Pazner S, deCamp A, B Gilbert P, Williams C, Yates N, Williams W, et al.
PLoS One
. 2014 Feb;
9(2):e87572.
PMID: 24504509
Unlabelled: In the RV144 HIV-1 vaccine efficacy trial, IgG antibody (Ab) binding levels to variable regions 1 and 2 (V1V2) of the HIV-1 envelope glycoprotein gp120 were an inverse correlate...
6.
Zolla-Pazner S, deCamp A, Cardozo T, Karasavvas N, Gottardo R, Williams C, et al.
PLoS One
. 2013 Jan;
8(1):e53629.
PMID: 23349725
The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy...
7.
Pepe M, Gu J, Morris D
Cancer Epidemiol Biomarkers Prev
. 2010 Feb;
19(3):655-65.
PMID: 20160267
Background: Advances in biotechnology have raised expectations that biomarkers, including genetic profiles, will yield information to accurately predict outcomes for individuals. However, results to date have been disappointing. In addition,...
8.
Morris D, Pepe M, Barlow W
Med Decis Making
. 2010 Feb;
30(4):484-98.
PMID: 20147599
Background: Statistical evaluation of medical imaging tests used for diagnostic and prognostic purposes often employs receiver operating characteristic (ROC) curves. Two methods for ROC analysis are popular. The ordinal regression...
9.
Qin L, Beyer R, Hudson F, Linford N, Morris D, Kerr K
BMC Bioinformatics
. 2006 Jan;
7:23.
PMID: 16417622
Background: There are currently many different methods for processing and summarizing probe-level data from Affymetrix oligonucleotide arrays. It is of great interest to validate these methods and identify those that...